Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant
about
Current perspectives on HIV-1 antiretroviral drug resistanceHigh-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.Structural Basis for the Inhibition of RNase H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed InhibitorsCrystal Structure of tert -Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding Pocket8-Modified-2'-deoxyadenosine analogues induce delayed polymerization arrest during HIV-1 reverse transcriptionFactors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patientsGlobal Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors.Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures.Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence.Allosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor bindingEvaluation of anti-HIV-1 mutagenic nucleoside analogues.Differential isotopic enrichment to facilitate characterization of asymmetric multimeric proteins using hydrogen/deuterium exchange mass spectrometry.The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase.Acetylenic linkers in lead compounds: a study of the stability of the propargyl-linked antifolates.In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C SubstitutionsStructural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.Efavirenz binding site in HIV-1 reverse transcriptase monomers.The interplay of structure and dynamics: insights from a survey of HIV-1 reverse transcriptase crystal structures.HIV reverse transcriptase: structural interpretation of drug resistant genetic variants from India.Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma.Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT.Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.Drug resistant mechanism of diaryltriazine analog inhibitors of HIV-1 reverse transcriptase using molecular dynamics simulation and 3D-QSAR.Current state-of-the-art in preclinical and clinical development of novel non-nucleoside HIV-1 reverse transcriptase inhibitors
P2860
Q26852626-F7A9214D-186F-44D0-AB5E-E361F0643109Q27649731-11280CB7-264D-4777-A79B-FB4EBF6F8ADCQ27661750-4258FC1A-E8C3-4409-89F4-708B667507D6Q27667348-61528E4C-89A2-4CD5-81C1-856BCC727316Q28477840-B5F9DEFF-521F-4985-85CB-4F077FA803E6Q33558937-2535BA3C-1E49-40CF-A2B3-91AC67ED410AQ33565179-DD63887C-64FA-415A-88ED-54A22570C14FQ33635679-6CF8C11F-9E9A-4601-98B5-D7BB58A7F9F4Q33768822-6BEBDB88-AE47-4F95-B011-038EE32D81CAQ34163065-301D7C48-2B03-40F0-9572-E30187257945Q34181367-F411A58B-E8A5-48DD-A8DD-795EB129F92DQ34313002-66F40605-2848-4F47-A3E6-1E32EC17DE90Q34439424-C1F58FF8-3960-429D-9A37-51C1EF07A79AQ34801497-EE4BD2B5-3DB1-4F73-96C3-10BD52EC46A1Q35654238-BF08C0CE-0351-4B02-B87F-81C543E12149Q35859896-BAF1C545-61F7-4313-BD5B-E6F0DA0B814AQ36244591-4AB7397A-DDB3-4CEA-A40B-05332EEA7DB7Q36296178-CB057527-148F-4278-BAB9-155B18A1FC02Q37643598-B536B326-3F5B-49C7-B789-9CE6484BA6D1Q37730522-5E88A273-289E-43F2-9C25-08A4652DD988Q39350740-4F5470D8-AEE3-411B-9A65-A927B7970FF6Q39912641-7DAF0E29-051C-498B-8797-F3F69BDA3D4AQ41040182-B75A3EF4-A13B-44F2-92BD-0D3825A02895Q41480004-847AD2FA-B3B2-47E1-BCC5-34F6A3A75E0DQ41761359-2B7CA3CF-6773-47AF-A6BB-BCD158BA3983Q42601729-67FA2251-00BB-413D-A79F-EA703ED50BCDQ42738742-FD66F421-6A97-4807-8A52-11CB15C69BADQ44579682-7CDF3DCF-6107-40B6-877B-7153BE5A7FADQ46230871-F7F05D23-390F-4E06-A5FC-1E0E2648EE76Q50107451-377F1142-08C9-4D5B-BCAD-F0F6FA32EBD3Q54549089-6B006FCE-9CD9-4516-A7D4-AC9E4CC78128Q54579751-A16F7ED2-0A2B-4137-979A-B020E9FA0944Q54628424-A2E295CB-CF52-4844-B971-26EEFA35C065Q57266180-224C489C-C710-45BC-B670-BB0D0C8B3031
P2860
Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant
@ast
Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant
@en
Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant
@nl
type
label
Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant
@ast
Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant
@en
Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant
@nl
prefLabel
Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant
@ast
Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant
@en
Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant
@nl
P2093
P2860
P3181
P1433
P1476
Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant
@en
P2093
Christer Sahlberg
Hans O Andersson
Hong Zhang
Jimmy Lindberg
Kerstin Fridborg
Rolf Noréen
Seved Löwgren
Torsten Unge
P2860
P304
P3181
P356
10.1046/J.1432-1327.2002.02811.X
P407
P577
2002-03-01T00:00:00Z